"Venture Philanthropists" Fill A Gap In Funding Early Stages Of Drug Discovery
In the article, C&EN associate editor Lisa Jarvis describes how venture capital firms have shifted away from investment in early-stage drug development, which provides "seed money" for start-up firms to begin work on promising new drugs. Those firms now are putting cash into the later stages of drug development and commercialization, where risks are smaller and marketable products are more likely to result.
The shift in priorities has resulted in emergence of the venture philanthropy movement, in which non-profit organizations, such as the Cystic Fibrosis Foundation, have become an important source of money for early-stage drug discovery. At that stage, academic scientists, entrepreneurs and start-up companies are seeking money for research to validate ideas for new drugs. Jarvis surveys the venture philanthropy landscape, and explains how disease advocacy groups have become major players in the for-profit world of biotech startups.
ARTICLE: "Sowing the Seeds of Much-Needed Cures: As Venture capitalists' priorities shift,. venture philanthropists fill the gap in funding of drug discovery by biotechs"
----------------------------
Article adapted by Start Sanatate from original press release.
----------------------------
American Chemical Society News Service
The American Chemical Society - the world's largest scientific society - is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.
Contact: Michael Woods
American Chemical Society
"Venture Philanthropists" umple un gol de finanþare în stadii incipiente de descoperire de droguri - "Venture Philanthropists" Fill A Gap In Funding Early Stages Of Drug Discovery - articole medicale engleza - startsanatate